MidLantic Urology
MidLantic Urology
Bala-Cynwyd, Pennsylvania, United States27 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Metastatic Hormone-sensitive Prostate Cancer | Active, not recruiting | Phase 2 | 2026-10-09 | NCT06991556 | |
| Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer | Intermediate Risk Non-Muscle Invasive Bladder Cancer | Recruiting | Phase 3 | 2026-10-07 | NCT06510374 | |
| Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2026-10-02 | NCT01436968 | |
| Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Non-Muscle Invasive Bladder Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Recruiting | Phase 2 | 2026-09-29 | NCT06995677 | |
| A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Non-Muscle Invasive Bladder Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Recruiting | Phase 3 | 2026-09-28 | NCT06919965 | |
| A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Prostatic Neoplasms, Castration-Resistant, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 3 | 2026-09-25 | NCT07225946 | |
| A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Prostatic Neoplasms, Castration-Resistant, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 3 | 2026-09-25 | NCT07164443 | |
| A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer | Non-muscle Invasive Bladder Cancer With Carcinoma in Situ | Recruiting | Phase 3 | 2026-09-25 | NCT06545955 | |
| A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Non-Muscle Invasive Bladder Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Recruiting | Phase 3 | 2026-09-25 | NCT06319820 | |
| A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, neoplasm, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Active, not recruiting | Phase 3 | 2026-09-25 | NCT04658862 | |
| A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2026-09-25 | NCT04557059 | |
| A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2026-09-25 | NCT03767244 | |
| A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Prostatic Cancer, Castration-Resistant, Prostatic Neoplasms, Castration-Resistant, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2026-09-25 | NCT03748641 | |
| This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 3 | 2026-09-24 | NCT07028853 | |
| Sacral Neuromodulation for Male Overactive Bladder (MOAB) | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Lower Urinary Tract Symptoms, Male Urogenital Diseases, Neoplasms by Site, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, Urological Manifestations, benign prostatic hyperplasia, male reproductive organ cancer, male reproductive system disorder, neoplasm, overactive bladder, prostate cancer, prostate disorder, urinary bladder disorder, urinary system disorder | Recruiting | Not applicable | 2026-09-14 | NCT06511141 | |
| SpaceIT Hydrogel System for Perirectal Spacing | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Not applicable | 2026-09-14 | NCT06451614 | |
| 177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2026-09-04 | NCT05204927 | |
| Trial of Ureteroscopy vs Steerable Continuous Flow Aspiration Technology | Calculi, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Kidney Calculi, Male Urogenital Diseases, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Urinary Calculi, Urogenital Diseases, kidney disorder, nephrolithiasis, urinary system disorder, urolithiasis | Recruiting | Not applicable | 2026-07-23 | NCT07101809 | |
| Study of ORIC-944 in Patients With Metastatic Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, metastatic prostate carcinoma, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 1 | 2026-07-09 | NCT05413421 | |
| A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT | Cancer of Urinary Tract, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Non-Muscle Invasive Bladder Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, urothelial carcinoma | Active, not recruiting | Phase 3 | 2026-07-01 | NCT06111235 | |
| A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Male Urogenital Diseases, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2026-07-01 | NCT05288166 | |
| Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Not applicable | 2026-06-15 | NCT05683691 | |
| A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2026-05-14 | NCT03574571 | |
| A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Non-Muscle Invasive Bladder Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-03-31 | NCT02138734 | |
| INTIBIA Pivotal Study | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Lower Urinary Tract Symptoms, Male Urogenital Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urinary Incontinence, Urinary Incontinence, Urge, Urination Disorders, Urogenital Diseases, Urological Manifestations, overactive bladder, urinary bladder disorder, urinary system disorder | Active, not recruiting | Not applicable | 2026-03-02 | NCT05250908 |